Immunodeficiency-associated viral oncogenesis

Clinical Microbiology and Infection

Volumn 21, Issue 11, 2015, Pages 975-983

  Pierangeli, A ^a   Antonelli, G ^a   Gentile, G ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Carcinogenesis; HIV; Immunodeficiency; Transplantation; Viral oncogenesis

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANUS CANCER; BURKITT LYMPHOMA; CANCER RISK; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; EPIDERMODYSPLASIA VERRUCIFORMIS; EPSTEIN BARR VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HODGKIN DISEASE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T-LYMPHOTROPIC VIRUS 1; IMMUNE DEFICIENCY; KAPOSI SARCOMA; LARGE CELL LYMPHOMA; MEAN CORPUSCULAR VOLUME; MERKEL CELL TUMOR; NK T CELL LYMPHOMA; NON MELANOMA SKIN CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; WART VIRUS; CARCINOGENESIS; COMPLICATION; GROWTH, DEVELOPMENT AND AGING; IMMUNOCOMPROMISED PATIENT; NEOPLASMS; PATHOLOGY; TUMOR VIRUS; VIROLOGY; VIRUS INFECTION;

CARCINOGENESIS; HUMANS; IMMUNOCOMPROMISED HOST; NEOPLASMS; ONCOGENIC VIRUSES; VIRUS DISEASES;

EID: 84945436710     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.07.009     Document Type: Review

References (97)

1. Moore P.S., Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer 2010, 10:878-889.
2. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
3. International Agency for Research on Cancer Epstein-Barr virus and Kaposi's sarcoma virus/human herpes virus 8 1997, World Health Organization, Lyon.
4. de Martel C., Ferlay J., Franceschi S., Vignat J., Forman D., Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012, 13:607-615.
5. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009, 10:321-322.
6. Robbins H.A., Shiels M.S., Pfeiffer R.M., Engels E.A. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS 2014, 28:881-890.
7. Pinzone M.R., Beretta M., Cacopardo B., Nunnari G. Epstein-Barr virus and Kaposi sarcoma-associated herpesvirus-related maligancies in the setting of human immunodeficiency virus infection. Semin Oncol 2015, 42:258-271.
8. Guiguet M., Boué F., Cadranel J., Lang J.M., Rosenthal E., Costagliola D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009, 10:1152-1159. Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort.
9. De Roos A.J., Mirick D.K., Edlefsen K.L., LaCroix A.Z., Kopecky K.J., Madeleine M.M., et al. Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma. Cancer Res 2012, 72:4733-4743.
10. Engels E.A., Pfeiffer R.M., Landgren O., Moore R.D. Immunologic and virologic predictors of AIDS-related non-Hodgkin lymphoma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr 2010, 54:78-84.
11. Grulich A.E., van Leeuwen M.T., Falster M.O., Vajdic C.M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007, 370:59-67.
12. Engels E.A., Pfeiffer R.M., Fraumeni J.F., Kasiske B.L., Israni A.K., Snyder J.J., et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011, 306:1891-1901.
13. Quinlan C.S., Pfeiffer R.M., Morton L.M., Engels E.A. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in United States. Am J Hematol 2011, 86:206-209.
14. Nourse J.P., Jones K., Gandhi M.K. Epstein-Barr virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy. Am J Transplant 2011, 11:888-895.
15. Rasche L., Kapp M., Heinsele H., Mielke S. EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoietic SCT. Bone Marrow Transplant 2014, 49:163-167.
16. International Agency for Research on Cancer working group on the evaluation of carcinogenic risk to humans Biological agents, Volume 100B: a review of human carcinogens. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 2012, IARC Press, Lyon.
17. Kowalkowski M.A., Mims M.A., Day R.S., Du X.L., Chan W., Chiao E.Y. Longer duration of combination antiretroviral therapy reduces the risk of Hodgkin lymphoma: a cohort study of HIV-infected male veterans. Cancer Epidemiol 2014, 38:386-392.
18. Quinlan S.C., Landgren O., Morton L.M., Engels E.A. Hodgkin lymphoma among US solid organ transplant recipients. Transplantation 2010, 90:1011-1015.
19. Cesarman E. Gammaherpesviruses and lymphoproliferative disorders. Annu Rev Pathol Mech Dis 2014, 9:349-372.
20. Vereide D.T., Sugden B. Lymphomas differ in their dependence on Epstein-Barr virus. Blood 2011, 117:1977-1985.
21. Arvey A., Ojesina A.I., Pedamallu C.S., Ballon G., Jung J., Duke F., et al. The tumor virus landscape of AIDS-related lymphomas. Blood 2015, 125:e14-e22.
22. Tempera I., Lieberman P.M. Epigenetic regulation of EBV persistence and oncogenesis. Semin Cancer Biol 2014, 26:22-29.
23. Dolcetti R. Cross-talk between Epstein-Barr virus and microenvironment in the pathogenesis of lymphomas. Semin Cancer Biol 2015 May 4, pii: S1044-579X(15)00031-0. [Epub ahead of print]. 10.1016/j.semcancer.2015.04.006.
24. Yanik E.L., Napravnik S., Cole S.R., Achenbach C.J., Gopal S., Olshan A., et al. Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis 2013, 57:756-764.
25. Gérard L., Bérezné A., Galicier L., Meignin V., Obadia M., De Castro N., et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease. ANRS 117 Castleman Trial. J Clin Oncol 2007, 25:3350-3356.
26. Stallone G., Schena A., Infante B., Di Paolo S., Loverre A., Maggio G., et al. Sirolimus for Kaposi's sarcoma in renal transplant recipients. N Engl J Med 2005, 35:1317-1323.
27. Gentile G., Capobianchi A., Volpi A., Palù G., Pica F., Calistri A., et al. Human herpesvirus 8 DNA in serum during seroconversion in allogeneic bone marrow transplant recipients. J Natl Cancer Inst 2005, 97:1008-1011.
28. Lebbe C., Legendre C., Frances C. Kaposi's sarcoma in transplantation. Transplant Rev (Orlando) 2008, 22:252-261.
29. Laney A.S., Dollard S.C., Jaffe H.W., Offermann M.K., Spira Tj, Gunthel C.J., et al. Repeated measures study of human herpesvirus 8 (HHV-8) DNA and antibodies in man seropositive for both HHV-8 and HIV. AIDS 2004, 18:1819-1826.
30. Capobianchi A., Iori A.P., Mauro F.R., Torelli G.F., Micozzi A., Girmenia C., et al. Longitudinal analysis of human herpesvirus-8 DNA and antibodies in a Italian allogeneic stem cell transplant recipient. J Clin Virol 2011, 52:247-250.
31. Bhutani M., Polizzotto M., Uldrick T., Yarchoan R. Kaposi sarcoma-associated herpes-virus-associated malignancies: epidemiology, pathogenesis, and advances in treatment. Semin Oncol 2015, 42:223-246.
32. Christenson E.S., Teply B., Agrawal V., Illei P., Gurakar A., Kanakry J.A. Human herpesvirus 8-related primary effusion lymphoma after liver transplantation. Am J Transplant 2015, XX:1-5.
33. Powles T., Stebbing J., Bazeos A., Hatzimichael E., Mandalia S., Nelson M., et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Ann Oncol 2009, 20:775-779.
34. Gramolelli S., Schulz T.F. The role of Kaposi sarcoma-associated herpesvirus in the pathogenesis of Kaposi sarcoma. J Pathol 2015, 235:368-380.
35. Lieberman P.M. Keeping it quiet: chromatin control of gammaherpesvirus latency. Nat Rev Microbiol 2013, 11:863-875.
36. Dittmer D.P., Damania B. Kaposi sarcoma associated herpesvirus pathogenesis (KSHV)-an update. Curr Opin Virol 2013, 3:238-244.
37. Verdonck K., González E., Van Dooren S., Vandamme A.M., Vanham G., Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007, 7:266-281.
38. Ishitsuka K., Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Infect Dis 2014, 15:e517-e526.
39. Gessain A., Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 2012, 3:388.
40. Matsuoka M., Jeang K.T. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: Viral infectivity, Tax, HBZ and therapy. Oncogene 2011, 30:1379-1389.
41. Cook L.B., Elemans M., Rowan A.G., Asquith B. HTLV-1: persistence and pathogenesis. Virology 2013, 435:131-140.
42. Ghezeldasht S.A., Shirdel A., Assarehzadegan M.A., Hassannia T., Rahimi H., Miri R., et al. Human T lymphotropic virus type I (HTLV-I) oncogenesis: molecular aspects of virus and host interactions in pathogenesis of adult T cell leukemia/lymphoma (ATL). Iran J Basic Med Sci 2013, 16:179-195.
43. Akagi T., Ono H., Shimotohno K. Characterization of T cells immortalized by Tax1 of human T-cell leukemia virus type 1. Blood 1995, 86:4243-4249.
44. Nerenberg M., Hinrichs S.H., Reynolds R.K., Khoury G., Jay G. The tat gene of human T-lymphotropic virus type 1 induces mesenchymal tumors in transgenic mice. Science 1987, 237:1324-1329.
45. Matsuoka M. HTLV-1 bZIP factor gene: its roles in HTLV-1 pathogenesis. Mol Aspects Med 2010, 31:359-366.
46. Bangham C.R., Cook L.B., Melamed A. HTLV-1 clonality in adult T-cell leukaemia and non-malignant HTLV-1 infection. T-cell leukemia/lymphoma. Semin Cancer Biol 2014, 26:89-98.
47. Nakagawa M., Nakagawa-Oshiro A., Karnan S., Tagawa H., Utsunomiya A., Nakamura S., et al. Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult. Clin Cancer Res 2009, 15:30-38.
48. Gentile G., Mele A., Monarca B., Vitale A., Pulsoni A., Visani G., et al. Hepatitis B and C viruses, human T-cell lymphotropic virus types 1 and 2 and leukemias: a case control study. Cancer Epidemiol Biomarkers Prev 1996, 5:227-230.
49. Iwanaga M.I., Watanabe T., Utsunomiya A., Okayama A., Uchimaru K., Koh K.R., et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 2010, 116:1211-1219.
50. Kawano N., Shimoda K., Ishikawa F., Taketomi A., Yoshizumi T., Shimoda S., et al. Adult T-cell leukemia development from a human virus T-cell leukemia virus type I carrier after a living donor liver transplantation. Transplantation 2006, 82:840-843.
51. Hoshida Y., Li T., Dong Z., Tomita Y., Yamauchi A., Hanai J., et al. Lymphoproliferative disorders in renal transplant patients in Japan. Int J Cancer 2001, 91:869-875.
52. Tamaki H., Matsuoka M. Donor-derived T-cell leukemia after bone marrow transplantation. N Engl J Med 2006, 354:1758-1759.
53. Yoshizumi T., Shirabe K., Ikegami T., Kayashima H., Yamashita N., Morita K., et al. Impact of human T-cell leukemia virus type 1 in living donor liver transplantation. Am J Transplant 2012, 12:1479-1485.
54. Kaul D.R., Davis J.A. Human T cell lymphotrophic virus 1/2 in solid organ transplantation. Am J Transplant 2013, 13:355-360. AST Infectious Diseases Community of Practice.
55. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55:244-265.
56. Dalianis T. Human papillomavirus and oropharyngeal cancer, the epidemics, and significance of additional clinical biomarkers for prediction of response to therapy. Int J Oncol 2014, 44:1799-1805.
57. Quint K.D., Genders R.E., de Koning M.N., Borgogna C., Gariglio M., Bouwes Bavinck J.N., et al. Human beta-papillomavirus infection and keratinocyte carcinomas. J Pathol 2015, 235:342-354.
58. Palefsky J.M., Minkoff H., Kalish L.A., Levine A., Sacks H.S., Garcia P., et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999, 91:226-236.
59. Frisch M., Biggar R.J., Goedert J.J. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000, 92:1500-1510.
60. Chaturvedi A.K., Madeleine M.M., Biggar R.J., Engels E.A. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009, 101:1120-1130.
61. Robbins H.A., Pfeiffer R.M., Shiels M.S., Li J., Hall H.I., Engels E.A. Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst 2015, 107. pii: dju503. 10.1093/jnci/dju503.
62. Franceschi S., Lise M., Clifford G.M., Rickenbach M., Levi F., Maspoli M., et al. Changing patterns of cancer incidence in the early- and late-ART periods: the Swiss HIV Cohort Study. Br J Cancer 2010, 103:416-422.
63. Blitz S., Baxter J., Raboud J., Walmsley S., Rachlis A., Smaill F., et al. Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women. J Infect Dis 2013, 208:454-462.
64. Gravitt P.E. The known unknowns of HPV natural history. J Clin Invest 2011, 121:4593-4599.
65. Maglennon G.A., McIntosh P.B., Doorbar J. Immunosuppression facilitates the reactivation of latent papillomavirus infections. J Virol 2014, 88:710-716.
66. Theiler R.N., Farr S.L., Karon J.M., Paramsothy P., Viscidi R., Duerr A., et al. High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding. Obstet Gynecol 2010, 115:1150-1158.
67. Rositch A.F., Burke A.E., Viscidi R.P., Silver M.I., Chang K., Gravitt P.E. Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. Cancer Res 2012, 72:6183-6190.
68. Meeuwis K.A., Hilbrands L.B., IntHout J., Slangen B.F., Hendriks I.M., Hinten F., et al. Cervicovaginal HPV infection in female renal transplant recipients: an observational, self-sampling based, cohort study. Am J Transplant 2015, 15:723-733.
69. Nazac A., Fridmann S., Boufassa F. Is the level of proof of the North American Multicohort Collaboration Prospective Study sufficient to conclude that incidence of invasive cervical cancer is higher in HIV-infected women?. J Acquir Immune Defic Syndr 2013, 63:e163-e164.
70. Abraham A.G., Strickler H.D., D'Souza G. Invasive cervical cancer risk among HIV-infected women is a function of CD4 count and screening. J Acquir Immune Defic Syndr 2013, 63:e163.
71. Huchko M.J., Leslie H., Sneden J., Maloba M., Abdulrahim N., Bukusi E.A., et al. Risk factors for cervical precancer detection among previously unscreened HIV-infected women in Western Kenya. Int J Cancer 2014, 134:740-745.
72. Thorsteinsson K., Ladelund S., Jensen-Fangel S., Katzenstein T.L., Johansen I.S., Pedersen G., et al. Adherence to the cervical cancer screening program in women living with HIV in Denmark: Comparison with the general population. BMC Infect Dis 2014, 14:256.
73. Silverberg M.J., Lau B., Justice A.C., Engels E., Gill M.J., Goedert J.J., et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012, 54:1026-1034.
74. Rodger A.J., Lodwick R., Schechter M., Deeks S., Amin J., Gilson R., et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013, 27:973-979.
75. Piketty C., Selinger-Leneman H., Bouvier A.M. Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the French hospital database on HIV. J Clin Oncol 2012, 30:4360-4366.
76. Worm S.W., Bower M., Reiss P., Bonnet F., Law M., Fätkenheuer G., et al. Non-AIDS defining cancers in the D: A:D Study-time trends and predictors of survival: a cohort study. BMC Infect Dis 2013, 13:471.
77. Berry J.M., Jay N., Cranston R.D., Darragh T.M., Holly E.A., Welton M.L., et al. Progression of anal high-grade squamous intraepithelial lesions to invasive anal cancer among HIV-infected men who have sex with men. Int J Cancer 2014, 134:1147-1155.
78. Borges A.H., Dubrow R., Silverberg M.J. Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk. Curr Opin HIV AIDS 2014, 9:34-40.
79. Rajasuriar R., Wright E., Lewin S.R. Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damage. Curr Opin HIV AIDS 2015, 10:35-42.
80. Chow W.A., Jiang C., Guan M. Anti-HIV drugs for cancer therapeutics: back to the future?. Lancet Oncol 2009, 10:61-71.
81. Bruyand M., Ryom L., Shepherd L., Fatkenheuer G., Grulich A., Reiss P., et al. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the d:a:d study. J Acquir Immune Defic Syndr 2015, 68:568-577.
82. Muller K., Kazimiroff J., Fatahzadeh M., Smith R.V., Wiltz M., Polanco J., et al. Oral human papillomavirus infection and oral lesions in HIV-positive and HIV-negative dental patients. J Infect Dis 2015, 212:760-768. pii: jiv080. [Epub ahead of print].
83. Beachler D.C., Guo Y., Xiao W., Burk R.D., Minkoff H., Strickler H.D., et al. High oral HPV16 viral load predicts long-term persistence in HIV-infected and at risk HIV-uninfected individuals. J Infect Dis 2015, pii: jiv273. [Epub ahead of print].
84. Jablonska S., Dabrowski J., Jakubowicz K. Epidermodysplasia verruciformis as a model in studies on the role of papovaviruses in oncogenesis. Cancer Res 1972, 32:583-589.
85. Wieland U., Kreuter A., Pfister H. Human papillomavirus and immunosuppression. Curr Probl Dermatol 2014, 45:154-165.
86. Howley P.M., Pfister H.J. Beta genus papillomaviruses and skin cancer. Virology 2015, 479-480:290-296.
87. Ramoz N., Rueda L.A., Bouadjar B., Montoya L.S., Orth G., Favre M. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 2002, 32:579-581.
88. Frecha C., Chevalier S.A., van Uden P., Rubio I., Siouda M., Saidj D., et al. Expression of the epidermodysplasia verruciformis-associated genes EVER1 and EVER2 is activated by exogenous DNA and inhibited by LMP1 oncoprotein from Epstein-Barr virus. J Virol 2015, 89:1461-1467.
89. Kawai T., Malech H.L. WHIM syndrome: congenital immune deficiency disease. Curr Opin Hematol 2009, 16:20-26.
90. Chow K.Y., Brotin É., Ben Khalifa Y., Carthagena L., Teissier S., Danckaert A., et al. A pivotal role for CXCL12 signaling in HPV-mediated transformation of keratinocytes: clues to understanding HPV-pathogenesis in WHIM syndrome. Cell Host Microbe 2010, 8:523-533.
91. Connolly K., Manders P., Earls P., Epstein R.J. Papillomavirus-associated squamous skin cancers following transplant immunosuppression: One Notch closer to control. Cancer Treat Rev 2014, 40:205-214.
92. Albores-Saavedra J., Batich K., Chable-Montero F., Sagy N., Schwartz A.M., Henson D.E. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol 2010, 37:20-27.
93. Feng H., Shuda M., Chang Y., Moore P.S. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008, 319:1096-1100.
94. Bouvard V., Baan R.A., Grosse Y., Lauby-Secretan B., El Ghissassi F., Benbrahim-Tallaa L., et al. Carcinogenicity of malaria and of some polyomaviruses. Lancet Oncol 2012, 13:339-340.
95. Ma J.E., Brewer J.D. Merkel cell carcinoma in immunosuppressed patients. Cancers (Basel) 2014, 6:1328-1350.
96. Clarke C.A., Robbins H.A., Tatalovich Z., Lynch C.F., Pawlish K.S., Finch J.L., et al. Risk of Merkel cell carcinoma after solid organ transplantation. J Natl Cancer Inst 2015, 107(2). pii: dju382. 10.1093/jnci/dju382.
97. Wieland U., Kreuter A. Merkel cell polyomavirus infection and Merkel cell carcinoma in HIV-positive individuals. Curr Opin Oncol 2011, 23:488-493.